Pearl Therapeutics Secures $65,000,000 Series D Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8e8a109a-13b8-4d3a-8aa0-2319d959b2e7&Preview=1
Date
11/13/2012
Company Name
Pearl Therapeutics
Mailing Address
200 Saginaw Drive Redwood City, CA 94063
Company Description
Pearl Therapeutics is focused on developing a pipeline of novel and
superior products for chronic respiratory disorders, providing patients
with advanced therapeutic options in familiar and well accepted dosage
forms. The company has licensed advanced particle technology from Nektar
Therapeutics (Nasdaq: NKTR) for developing a series of products in selected
therapeutic fields.
Website
http://www.pearltherapeutics.com
Transaction Type
Venture Equity
Transaction Amount
$65,000,000
Transaction Round
Series D
Proceeds Purposes
Proceeds from this financing will be used by Pearl to start Phase 3 for PT003, Pearl’s lead candidate product comprised of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist (LABA) delivered via a metered dose inhaler (HFA MDI).
M&A Terms
Venture Investor
Vatera Healthcare Partners
Venture Investor
5AM Ventures
Venture Investor
New Leaf Venture Partners
Venture Investor
Clarus Ventures